List view / Grid view
The EMA’s pharmacovigilance committee (PRAC) began reviewing terlipressin containing medicines and recommended updates to COVID-19 vaccine safety information.
A new cell therapy has been tested in patients with liver cirrhosis and found no significant adverse effects.
Researchers have discovered evidence that stomach acid suppression alters specific gut bacteria in a way that promotes liver injury and progression of three types of chronic liver disease...
Primary sclerosing cholangitis is a currently incurable liver disorder, primarily affecting younger adults aged between 30 and 40.
29 July 2016 | By Mandy Parrett, Editorial Assistant
Shire Plc has announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP626 (volixibat) for an investigational treatment of adults with nonalcoholic steatohepatitis (NASH) with liver fibrosis.